Stanford researchers have shown that systemic treatment with beta-amyloid peptides could reduce inflammation in mouse models of multiple sclerosis. Cardinal Therapeutics has licensed the work along with related technologies and now is trying to develop anti-inflammatory compounds based on the mechanism.